Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
| ▸ | LTK | P29376 | 2/20 | 0.35 |
| ▸ | MST1R | Q04912 | 2/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152310 | 0.78 | CDK5 (0.44) | CLK4ROCK1CDK5DYRK1APIM1 | |
| SCHEMBL21153005 | 0.69 | KDR (0.43) | CLK4ROCK1CDK5DYRK1APIM1 | |
| SCHEMBL24525748 | 0.68 | MAP3K9 (0.31) | MAP3K9MAP3K11PDPK1 | |
| SCHEMBL21152484 | 0.66 | MAP3K5 (0.38) | — | |
| SCHEMBL14502277 | 0.65 | ALDH1A1 (0.36) | CLK4DYRK1ACSNK1A1DYRK1BPRKAA1 | |
| SCHEMBL2729715 | 0.64 | NUAK1 (0.35) | PIM1AURKBMETNEK2PTK2 | |
| SCHEMBL21152480 | 0.63 | PDE3B (0.33) | — | |
| SCHEMBL4188744 | 0.62 | MAOA (0.44) | — | |
| SCHEMBL30775313 | 0.61 | CLK4 (0.53) | CLK4ROCK1CDK5DYRK1APIM1 | |
| SCHEMBL9475196 | 0.60 | PARP1 (0.68) | CLK4ROCK1CDK5DYRK1APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735404-B1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2020046975-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019136025-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | CLK4 195/4885ROCK1 28/4885CDK5 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.